DOCSLIB.ORG

Research Portal Dépôt Institutionnel - Portail De La Recherche

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Portal Dépôt Institutionnel - Portail De La Recherche Institutional Repository - Research Portal Dépôt Institutionnel - Portail de la Recherche University of Namurresearchportal.unamur.be RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE Characterization of CYP26B1-selective inhibitor, DX314, as a potential therapeutic for keratinization disorders Veit, Joachim; DE GLAS, VALERIE; Balau, Benoit; Liu, Haoming; Bourlond, Florence; Paller, Amy; POUMAY, Yves; Diaz, Philippe Published in: The journal of investigative dermatology Author(s)DOI: - Auteur(s) : 10.1016/j.jid.2020.05.090 Publication date: 2021 PublicationDocument date Version - Date de publication : Peer reviewed version Link to publication Citation for pulished version (HARVARD): Veit, J, DE GLAS, VALERIE, Balau, B, Liu, H, Bourlond, F, Paller, A, POUMAY, Y & Diaz, P 2021, Permanent'Characterization link - Permalien of CYP26B1-selective : inhibitor, DX314, as a potential therapeutic for keratinization disorders', The journal of investigative dermatology, vol. 141, pp. 72-83. https://doi.org/10.1016/j.jid.2020.05.090 Rights / License - Licence de droit d’auteur : General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. BibliothèqueDownload date: Universitaire 07. oct.. 2021 Moretus Plantin Journal of Investigative Dermatology Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders Journal: Journal of Investigative Dermatology Manuscript ID JID-2020-0105.R2 Article Type:ForOriginal Review Article Only Date Submitted by the 29-Apr-2020 Author: Complete List of Authors: Veit, Joachim; University of Montana Missoula, Biomedical and Pharmaceutical Sciences De Glas, Valerie; University of Namur, URPHYM-NARLIS Balau, Benoît; University of Namur, URPHYM-NARLIS Liu, Haoming; Northwestern University Feinberg School of Medicine, Departments of Dermatology and Pediatrics Bourlond, Florence; Hôpital Erasme, Université Libre de Bruxelles, Service de Dermatologie Paller, Amy; Northwestern University Feinberg School of Medicine, Departments of Dermatology and Pediatrics Poumay, Yves; University of Namur, URPHYM-NARLIS Diaz, Philippe; University of Montana Missoula, Biomedical and Pharmaceutical Sciences; DermaXon LLC, R&D Drug Development, Keratinization Disorders, Barrier Function, Keywords: Pharmacology, Ichthyosis Page 1 of 51 Journal of Investigative Dermatology 1 2 3 Editor comments: 4 Section/Deputy Editor: 1 5 6 Comments to the Author: 7 Revision is responsive to reviewer comments and improved by revision. 8 9 We would like to thank the editors for their time and feedback regarding our submission. 10 11 The only change we are submitting in this revision is to a minor figure reference issue we found 12 in the Figure 4 legend. The reference to parts "(a,c,d)" in the last sentence was changed to 13 14 correctly read "(a,b,d)". This correction was highlighted and underlined in yellow in the 15 manuscript text. 16 17 18 Reviewer comments: 19 For Review Only 20 Reviewer: 1 21 Comments to the Author 22 This is a very careful Revision of an excellent paper. My concern on the experimental design used, namely 23 a simultaneous co-tratment with all trans retinoic acid in the keratinocyte cultures is well and fully 24 25 adressed and authors Point out that in the rhino mice model no cotratment was used, but similar effects 26 were achieved. Moreover, they clarify that in their in vitro conditions no RA precursors and no 27 appreciable levels of all trans retinoic acid will be present which justifies their Approach and they 28 provide several prominent references like that of Giltaire et al 2009 on this culture model. All specific 29 30 points have been fully and carefully adressed. No further comment. 31 32 33 Reviewer: 2 34 Comments to the Author 35 I believe that the authors have responded adequately to my questions. 36 37 We would like to sincerely thank reviewer #1 and reviewer #2 for their time, effort and 38 comments regarding our submission. 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Journal of Investigative Dermatology Page 2 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 For Review Only 20 21 22 23 24 25 26 27 28 29 30 527x355mm (96 x 96 DPI) 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Page 3 of 51 Journal of Investigative Dermatology 1 2 3 Informative Title: 4 5 Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for 6 7 Keratinization Disorders 8 9 10 Short Title: 11 12 DX314: Keratinization Disorder Therapeutic 13 14 15 16 Joachim G.S. Veit1, Valérie De Glas2, Benoît Balau2, Haoming Liu4, Florence Bourlond5, 17 4 2 1,3 18 Amy S. Paller , Yves Poumay , Philippe Diaz 19 For Review Only 20 21 1Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 22 2 23 URPHYM-NARLIS, University of Namur, Namur, Belgium 24 3DermaXon LLC, Missoula, MT 25 26 4Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of 27 28 Medicine, Chicago, IL 29 5 30 Service de Dermatologie, Hôpital Erasme, Université Libre de Bruxelles, Belgique 31 32 33 Correspondence: Philippe Diaz, Department of Biomedical and Pharmaceutical Sciences, 34 35 University of Montana, 32 Campus Dr., Missoula, MT, 59812. Email: 36 37 [email protected] 38 39 40 ORCIDs: 41 42 Joachim G.S. Veit: https://orcid.org/0000-0001-5908-0648 43 Valérie De Glas: https://orcid.org/0000-0001-7366-2601 44 45 Benoît Balau: https://orcid.org/0000-0002-7314-860X 46 47 Haoming Liu: https://orcid.org/0000-0002-3190-5422 48 49 Florence Bourlond: https://orcid.org/0000-0003-1071-3306 50 Amy S. Paller: https://orcid.org/0000-0001-6187-6549 51 52 Yves Poumay: http://orcid.org/0000-0001-5200-3367 53 54 Philippe Diaz: https://orcid.org/0000-0002-2339-8803 55 56 57 58 1 59 60 Journal of Investigative Dermatology Page 4 of 51 1 2 3 Abbreviations: RAMBA, retinoic acid metabolism blocking agents; atRA, all-trans-retinoic acid; 4 5 RHE, reconstructed human epidermis; TEER, transepithelial electrical resistance; TEWL, 6 7 transepidermal water loss; CYP26, cytochrome p450 family 26; DD, Darier disease; LI, lamellar 8 ichthyosis; RXLI, Recessive x-linked ichthyosis. See supplementary materials for additional 9 10 abbreviations (Table S4) 11 12 13 14 Funding: This work was supported by the by the National Institute of Arthritis and 15 Musculoskeletal and Skin Disease of the National Institutes of Health: R44AR069416 (PD), 16 17 P20GM103546 (PD, JV). The content of this paper is solely the responsibility of the authors and 18 19 does not necessarily reflectFor the official Review views of the National Only Institutes of Health. 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 2 59 60 Page 5 of 51 Journal of Investigative Dermatology 1 2 3 ABSTRACT 4 5 6 Inhibition of cytochrome P450 (CYP)-mediated retinoic acid (RA) metabolism by RA 7 8 metabolism blocking agents (RAMBAs) increases endogenous retinoids and is an alternative to 9 10 retinoid therapy. Currently available RAMBAs (i.e. liarozole and talarozole) tend to have fewer 11 12 adverse effects than traditional retinoids but lack target specificity. Substrate-based inhibitor 13 14 15 DX314 has enhanced selectivity for RA-metabolizing enzyme CYP26B1 and may offer an 16 17 improved treatment option for keratinization disorders such as congenital ichthyosis and Darier 18 19 disease. In this study we useFor RT-qPCR, Review RNA sequencing, Only pathway, upstream regulator, and 20 21 22 histological analyses to demonstrate that DX314 can potentiate the effects of all-trans-RA 23 24 (atRA) in healthy and diseased reconstructed human epidermis (RHE). We unexpectedly 25 26 discovered that DX314, but not atRA or previous RAMBAs, appears to protect epidermal barrier 27 28 29 integrity. Additionally, DX314-induced keratinization and epidermal proliferation effects are 30 31 observed in a rhino mice model. Altogether, results indicate that DX314 inhibits atRA 32 33 metabolism with minimal off-target activity and shows therapeutic similarity to topical retinoids 34 35 in vitro and in vivo. Findings of a unique barrier-protecting effect require further mechanistic 36 37 38 study but may lead to a novel strategy in barrier-reinforcing therapies. DX314 is a unique and 39 40 promising candidate compound for further study and development in the context of 41 42 keratinization disorders. 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 3 59 60 Journal of Investigative Dermatology Page 6 of 51 1 2 3 INTRODUCTION 4 5 6 Therapeutics targeting retinoid biopathways have been implemented in the clinical 7 8 treatment of keratinization disorders such as the congenital ichthyoses (Vahlquist et al. 2008), 9 10 Darier disease (DD) (Casals et al. 2009; Cooper and Burge 2003; Dicken et al. 1982; Steijlen et 11 12 al. 1993), and other skin disorders (e.g.
Load more

Recommended publications
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • © Copyright 2018 Faith M. Stevison
    © Copyright 2018 Faith M. Stevison In Vitro to In Vivo Translation of Complex Drug-Drug Interactions Involving Retinoic Acid Faith M. Stevison A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2018 Reading Committee: Nina Isoherranen, Chair Kenneth E. Thummel Yvonne S. Lin Program Authorized to Offer Degree: Pharmaceutics University of Washington Abstract In Vitro to In Vivo Translation of Complex Drug-Drug Interactions Involving Retinoic Acid Faith M. Stevison Chair of the Supervisory Committee: Professor and Vice Chair, Nina Isoherranen Pharmaceutics all-trans-retinoic acid (atRA), the active metabolite of vitamin A, is a ligand for several nuclear receptors and acts as a critical regulator of many physiological processes. The cytochrome P450 26 (CYP26) enzymes are responsible for atRA clearance and are potential drug targets to increase concentrations of endogenous atRA in a tissue-specific manner. The first project of this thesis aimed to establish the relationship between CYP26 inhibition, by the potent CYP26A1 and B1 inhibitor talarozole, and altered atRA concentrations in tissues, and to quantify the increase in endogenous atRA concentrations necessary to alter atRA signaling in target organs. The second part of this thesis focused on evaluating exogenous atRA and retinoid dosing on gene regulation. Several in vitro and preclinical studies have suggested that atRA down-regulates CYP2D6 expression and activity. Both atRA and its stereoisomer 13-cis retinoic acid (13cisRA) are used clinically, and steady state exposures of atRA are similar after dosing with atRA or 13cisRA. The second aim of this thesis was to determine whether 13-cis retinoic acid (13cisRA) or its active metabolites, atRA and 4-oxo-13cisRA, cause a drug-drug interaction (DDI) with CYP2D6, decreasing the clearance of the CYP2D6 probe dextromethorphan.
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APC Min/+ Mice
    Published OnlineFirst September 16, 2016; DOI: 10.1158/2326-6066.CIR-15-0038 Research Article Cancer Immunology Research Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/þ Mice Hweixian Leong Penny1, Tyler R. Prestwood1, Nupur Bhattacharya1, Fionna Sun1, Justin A. Kenkel1, Matthew G. Davidson1, Lei Shen1, Luis A. Zuniga2, E. Scott Seeley1, Reetesh Pai3, Okmi Choi1, Lorna Tolentino1, Jinshan Wang4, Joseph L. Napoli4, and Edgar G. Engleman1 Abstract Chronic intestinal inflammation accompanies familial adeno- exhibited further reductions in intestinal RA with concomitant matous polyposis (FAP) and is a major risk factor for colorectal increases in inflammation and tumor burden. Conversely, resto- cancer in patients with this disease, but the cause of such inflam- ration of RA by pharmacologic blockade of the RA-catabolizing mation is unknown. Because retinoic acid (RA) plays a critical role enzyme CYP26A1 attenuated inflammation and diminished in maintaining immune homeostasis in the intestine, we hypoth- tumor burden. To investigate the effect of RA deficiency on the esized that altered RA metabolism contributes to inflammation gut immune system, we studied lamina propria dendritic cells and tumorigenesis in FAP. To assess this hypothesis, we analyzed (LPDC) because these cells play a central role in promoting þ RA metabolism in the intestines of patients with FAP as well as tolerance. APCMin/ LPDCs preferentially induced Th17 cells, but þ APCMin/ mice, a model that recapitulates FAP in most respects. reverted to inducing Tregs following restoration of intestinal RA We also investigated the impact of intestinal RA repletion and in vivo or direct treatment of LPDCs with RA in vitro.
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Talarozole R enantiomer Catalog Number : T13422L CAS Number : 870093-23-5 Molecular Formula : C21H23N5S Molecular Weight : 377.51 Description: Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid. Storage: 2 years -80°C in solvent; 3 years -20°C powder; DMSO 51 mg/mL (135.10 mM) Solubility ( < 1 mg/ml refers to the product slightly soluble or insoluble ) Receptor (IC50) Others In vitro Activity Talarozole R enantiomer treatment increased the mRNA expression of CRABP2, KRT4, CYP26A1, and CYP26B1 dose- dependently, and decreased the expression of KRT2 and IL-1alpha compared with vehicle-treated skin. No mRNA change in retinol-metabolizing enzymes was obtained. There was no induction of epidermal thickness or overt skin inflammation in talarozole-treated skin. Immunofluorescence analysis confirmed the upregulation of KRT4 protein, but no upregulation of CYP26A1 and CYP26B1 expression was detected [1] [2]. In vivo Activity Talarozole R enantiomer slightly diffused into the skin only when dissolved in propylene glycol, isopropyl myristate, or ethanol. Although only 0.1% of the dose applied was found in the skin itself after 12-24 h, this was sufficient to achieve local concentrations well above the half-maximal inhibitory concentration value for talarozole. The distribution of talarozole within the skin was investigated: 80% was located in the epidermis, while the remaining 20% was found in the dermis [3]. Reference 1. Pavez Loriè E, Cools M, Borgers M, Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis.
    [Show full text]
  • Atra) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous Atra Signaling
    1521-009X/45/7/846–854$25.00 https://doi.org/10.1124/dmd.117.075341 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 45:846–854, July 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling Faith Stevison, Cathryn Hogarth, Sasmita Tripathy, Travis Kent, and Nina Isoherranen Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (F.S., S.T., N.I.); and School of Molecular Biosciences and the Center for Reproductive Biology, Washington State University, Pullman, Washington (C.H., T.K.) Received February 1, 2017; accepted April 18, 2017 ABSTRACT All-trans retinoic acid (atRA), the active metabolite of vitamin A, is a atRA concentrations in tissues. Following a single 2.5-mg/kg dose of Downloaded from ligand for several nuclear receptors and acts as a critical regulator of talarozole to mice, atRA concentrations increased up to 5.7-, 2.7-, and many physiologic processes. The cytochrome P450 family 26 (CYP26) 2.5-fold in serum, liver, and testis, respectively, resulting in induction enzymes are responsible for atRA clearance, and are potential drug of Cyp26a1 in the liver and testis and Rar b and Pgc 1b in liver. The targets to increase concentrations of endogenous atRA in a tissue- increase in atRA concentrations was well predicted from talarozole specific manner. Talarozole is a potent inhibitor of CYP26A1 and pharmacokinetics and in vitro data of CYP26 inhibition. After multiple CYP26B1, and has shown some success in clinical trials.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Cytochrome P450 Cyps
    Cytochrome P450 CYPs Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism. www.MedChemExpress.com 1 Cytochrome P450 Inhibitors, Activators & Modulators (+)-Ketoconazole (3S,5S)-Atorvastatin ((+)-Ketoconazol; (+)-R 41400) Cat. No.: HY-B0105A Cat. No.: HY-B0589C (+)-Ketoconazole ((+)-R 41400) is an imidazole (3S,5S)-Atorvastatin is a inactive enantiomer of anti-fungal agent, a CYP3A4 inhibitor. Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Purity: 99.51% Purity: ≥95.0% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg (Rac)-Brassinazole 1-Aminobenzotriazole Cat.
    [Show full text]
  • Cytochrome P450 Cyps
    Cytochrome P450 CYPs Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism. www.MedChemExpress.com 1 Cytochrome P450 Inhibitors & Modulators (+)-Ketoconazole (-)-Cephaeline dihydrochloride Cat. No.: HY-B0105A (NSC 32944) Cat. No.: HY-N2260 Bioactivity: (+)-Ketoconazole is an imidazole anti-fungal agent, a CYP3A4 Bioactivity: (-)-Cephaeline dihydrochloride is an enantiomer of Cephaeline inhibitor. Target: CYP3A4 (+)-Ketoconazole, an imidazole dihydrochloride. Cephaeline dihydrochloride is a selective anti-fungal agent, has often produced features of androgen CYP2D6 inhibtor with IC50 of 121 μM. deficiency including decreased libido, gynecomastia, impotence, oligospermia, and decreased testosterone levels, in… Purity: 99.51% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 2 mg, 5 mg 10 mg, 50 mg 1-Aminobenzotriazole 1-Ethynylnaphthalene (ABT; 3-Aminobenzotriazole) Cat.
    [Show full text]
  • Alterations in Endogenous Retinoids with Acute UVB Exposure and in the Progression of Cutaneous Squamous Cell Carcinoma
    Alterations in Endogenous Retinoids with Acute UVB Exposure and in the Progression of Cutaneous Squamous Cell Carcinoma THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Katherine Gressel Graduate Program in Human Nutrition The Ohio State University 2015 Master's Examination Committee: Dr. Helen Everts, Advisor Dr. Earl Harrison Dr. Tatiana Oberyszyn Copyrighted by Katherine Gressel 2015 Abstract Exposure to UVB light is the largest risk factor for the development of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the United States. UVB exposure causes many changes to occur in the skin such as epidermal thickening, hyperproliferation, and alterations to epidermal differentiation. Retinoids regulate the differentiation and proliferation of the epidermis. The purpose of this study is to examine how the expression of retinoid metabolism proteins in the epidermis is altered with acute UVB exposure and in the progression of cSCC. There is limited knowledge of how UVB exposure may affect this pathway; our results will allow us to gain a more complete understanding of changes in the entire retinoid metabolism pathway. We examined the expression of key retinoic acid metabolism proteins in the epidermis and hair follicle remnants 48 hours after UVB exposure in SKH-1 mice using immunohistochemistry. UVB exposure increased the expression of retinoid synthesis, degradation, and binding proteins. These changes in expression suggest that acute UVB exposure increases the synthesis of retinoic acid in the epidermis. Many of these proteins changed their localization in the epidermis, concentrating in the more differentiated cells of the stratum granulosum and stratum corneum.
    [Show full text]
  • Improved Homology Model of the Human All-Trans Retinoic Acid Metabolizing Enzyme CYP26A1
    molecules Article Improved Homology Model of the Human all-trans Retinoic Acid Metabolizing Enzyme CYP26A1 Mohamed K. A. Awadalla 1, Thamir M. Alshammari 2, Leif A. Eriksson 3,* and Patricia Saenz-Méndez 4 1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, P. O. Box 2440, 81451 Hail, Saudi Arabia; [email protected] 2 Department of Clinical Pharmacology, College of Pharmacy, University of Hail, P. O. Box 2440, 81451 Hail, Saudi Arabia; [email protected] 3 Department of Chemistry and Molecular Biology, University of Gothenburg, 40530 Gothenburg, Sweden 4 Computational Chemistry and Biology Group, Facultad de Química, UdelaR, 11800 Montevideo, Uruguay; [email protected] * Correspondence: [email protected]; Tel.: +46-031-786-9117 Academic Editor: Derek J. McPhee Received: 17 February 2016 ; Accepted: 9 March 2016 ; Published: 15 March 2016 Abstract: A new CYP26A1 homology model was built based on the crystal structure of cyanobacterial CYP120A1. The model quality was examined for stereochemical accuracy, folding reliability, and absolute quality using a variety of different bioinformatics tools. Furthermore, the docking capabilities of the model were assessed by docking of the natural substrate all-trans-retinoic acid (atRA), and a group of known azole- and tetralone-based CYP26A1 inhibitors. The preferred binding pose of atRA suggests the (4S)-OH-atRA metabolite production, in agreement with recently available experimental data. The distances between the ligands and the heme group iron of the enzyme are in agreement with corresponding distances obtained for substrates and azole inhibitors for other cytochrome systems. The calculated theoretical binding energies agree with recently reported experimental data and show that the model is capable of discriminating between natural substrate, strong inhibitors (R116010 and R115866), and weak inhibitors (liarozole, fluconazole, tetralone derivatives).
    [Show full text]
  • ( 12 ) United States Patent
    US009963439B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,963 , 439 B2 Diaz et al. ( 45 ) Date of Patent: May 8 , 2018 ( 54 ) SPECIFIC INHIBITORS OF CYTOCHROME FOREIGN PATENT DOCUMENTS P450 26 RETINOIC ACID HYDROXYLASE CN 102503857 6 / 2012 (71 ) Applicants : University of Washington Through its EP 0722928 A1 7 /1996 Center for Commercialization , Seattle, (Continued ) WA (US ) ; UNIVERSITY OF MONTANA , Missoula , MT (US ) OTHER PUBLICATIONS (72 ) Inventors : Philippe Diaz , Missoula , MT (US ); Ohta (Biorganic and Medicinal Chemistry Letters ; 23 , 2013 , 81 -84 ; Nina Isoherranen , Seattle , WA (US ) ; available online Nov. 15 , 2012 ). * Brian Buttrick , Seattle , WA (US ) ; (Continued ) Nicolas Guilloteau , Missoula , MT ( US ) Primary Examiner — Pancham Bakshi ( 73 ) Assignees: University of Washington Through Its (74 ) Attorney , Agent, or Firm — McDonnell Boehnen Center For Commercialization , Hulbert & Berghoff LLP Seattle , WA (US ) ; University of ( 57 ) ABSTRACT Montana , Missoula , MT (US ) The present disclosure is generally directed to compositions ( * ) Notice : Subject to any disclaimer, the term of this and methods for treating diseases that are ameliorated by the inhibition ofCYP26 mediated retinoic acid metabolism . The patent is extended or adjusted under 35 compositions comprise compounds of formula ( I ) . A rep U . S . C . 154 ( b ) by 0 days . days . reid50000060307390 IB /345 nullsents aryl optionally sub stituted with one , two, three , or four groups that are each ( 21) Appl . No. : 14 /912 , 479 independently halogen , cyano , nitro , C1- 6 alkyl , C1- 6 haloalkyl, - NH2, — NH ( C . - C . alkyl) , - N ( C / - C alkyl) 2 , (22 ) PCT Filed : Aug. 20 , 2014 OH , C , - Cô alkoxy , and C . - C6 haloalkoxy ; X is a bond , CH , CHR — - C = CHR NR4 — , ( 86 ) PCT No.
    [Show full text]